Skip to main content

Table 3 Response and MRD-negativity rates in patients with standard and high cytogenetic risk

From: Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

  Standard risk High riska
Response, n (%)b D-Vd (n = 135) Vd (n = 134) P value D-Vd (n = 39) Vd (n = 34) P value
ORR 113 (84) 83 (62) < 0.0001 33 (85) 19 (56) 0.0512
 ≥ CRc 38 (28) 13 (10)   11 (28) 2 (6)  
  sCR 12 (9) 3 (2)   4 (10) 0  
  CR 26 (19) 10 (8)   7 (18) 2 (6)  
 ≥ VGPRd 83 (62) 38 (28) < 0.0001 23 (59) 11 (32) 0.1259
  VGPR 45 (33) 25 (19)   12 (31) 9 (27)  
 PR 30 (22) 45 (34)   10 (26) 8 (24)  
MRD negative (10−5)e
n (%) 16 (11) 4 (3) 0.0091 6 (15) 0 0.0271
 Sustained MRD negativity (≥ 6 months), n (%) 9 (6) 3 (2) 0.1374 5 (13) 0 0.0569
 Sustained MRD negativity (≥ 12 months), n (%) 2 (1) 0 0.4982 3 (8) 0 0.2432
  1. CR complete response, D-Vd daratumumab plus bortezomib/dexamethasone, ITT intent-to-treat, MRD minimal residual disease, ORR overall response rate, PR partial response, sCR stringent complete response, Vd bortezomib/dexamethasone, VGPR very good partial response
  2. aPatients with high cytogenetic risk had a t(4;14), t(14;16), or del17p abnormality
  3. bResponse-evaluable population
  4. c≥ CR = sCR + CR
  5. d≥ VGPR = sCR + CR + VGPR
  6. eITT population (standard risk: D-Vd, n = 141; Vd, n = 140; high risk: D-Vd, n = 40; Vd, n = 35)